Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amer Sports Inc (AS) vs Bristol-Myers Squibb Co (BMY) Price & Performance

Amer Sports IncTrade
Bristol-Myers Squibb CoTrade

Price performance (Past 24H)

Key statistics

Amer Sports Inc vs Bristol-Myers Squibb Co — how do they compare? Amer Sports Inc trades at $34 (market cap $19.69B), while Bristol-Myers Squibb Co trades at $63.02 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 6.6× Amer Sports Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Amer Sports Inc pays none. Which is the better fit depends on your goals.

ASBMY
Market Cap
$19.69B$129.94B
Sector
TechnologyHealth
52-Week High
$41.96$65.89
52-Week Low
$29.54$42.60
Enterprise Value
$20.01B$163.92B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amer Sports Inc

No Aura AI signal available yet.

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.

The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amer Sports Inc

Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.

Read more on AS

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY